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Abstract
Background: Endothelin-1 (EDN1) has been involved in the development of airway obstruction
and inflammation in asthma. Several polymorphisms have been identified among the genes encoding
for preproET1, an inactive precursor of ET-1, and for ETA (EDNRA) and ETB (EDNRB), the two
receptors for EDN1. In the present work, we hypothesised that molecular variation in these genes
could be a major determinant of the degree of bronchial obstruction. The purpose of this study
was to investigate whether the genetic polymorphisms of preproET-1, EDNRA and EDNRB genes
were associated with the degree of airway obstruction, assessed by FEV1.
Methods: Polymorphisms of preproET-1, EDNRA and EDNRB were first studied in a population of
adult asthmatic patients. Results were confirmed in a large population of adults from the general
population from the ECRHS II study.
Results:  In our population of adult asthmatic patients, the EDNRB-30G>A (Leu277Leu)
polymorphism (GG genotype) is strongly associated with a low FEV1 and with a higher percentage
of patients with FEV1 < 80% of predicted value. No relationship was found between pulmonary
function and EDNRA-1363C>T (His323His) or preproET-1-595G>T (Lys198Asp) polymorphism.
In the adult population from the ECRHS II, we found a similar association between GG genotype
and a low FEV1 or a higher percentage of subjects with FEV1 < 80% predicted, especially in the
subgroups of asthmatics subjects (OR = 4.31 (95%CI 1.03 – 18.04)) and smokers (OR = 7.42
(95%CI 1.69 – 32.6)).
Conclusion: the EDNRB-30G>A polymorphism could be a determinant of airway obstruction in
humans with predisposing factors such as tobacco smoke exposure or asthma.
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Background
Asthma is a complex disorder characterised by airway
hyperresponsiveness and airway inflammation [1]. The
age-related rate of decline in lung function is greater in
adults with asthma than in those without asthma [2,3]
and is the result of chronic airway inflammation and air-
way remodelling [4]. The precise mechanisms underlying
the remodelling process are not totally understood [5] but
a genetic susceptibility has been suspected since all sub-
jects with asthma do not deteriorate their lung function
[2].
Endothelin-1 (EDN1) is a 21 amino acid peptide synthe-
sized from preproendothelin-1 (preproET-1), an inactive
precursor peptide encoded by a specific gene. PreproET-1
is cleaved by an endopeptidase to the intermediate form
namely "big-endothelin", then cleaved by the endothelin
converting enzyme to the mature form EDN1 [6]. There
are several lines of evidence suggesting that EDN1 may
play a role in the development of chronic airway obstruc-
tion in asthma [7,8]. EDN1 is strongly expressed in the
lung and is synthesised by many different cells including
epithelial cells, inflammatory cells and smooth muscle
cells [6,9,10]. Increased concentrations of EDN1 have
been found in the bronchial lavage of asthmatics [11],
and overexpression of EDN1 in the airways of asthmatic
patients has been demonstrated [12]. EDN1 may act as a
paracrine hormone causing sustained contraction of air-
way smooth muscle cells [13,14], accelerated growth of
both fibroblasts and airway smooth muscle cells [15,16]
and increased oedema formation and mucus secretion
[8], contributing to airway obstruction. EDN1 is impli-
cated in the initiation of eosinophilic airway inflamma-
tion [17]. Furthermore, chronic overexpression of human
EDN1 has been shown to induce peribronchial fibrosis in
transgenic mice [18].
The biological effects of EDN1 are mediated by the inter-
action of EDN1 with two specific receptors termed
EDNRA and EDNRB. Both receptors are present in the
human bronchial airways [19,20] but EDNRB is predom-
inant [19]. EDNRA has been involved in EDN1 induced
prostanoid and nitric oxide release and airway smooth
muscle proliferation [21], whereas EDNRB mediates the
contractile effect of EDN1 [19].
The genomic structure of human preproET-1, EDNRA and
EDNRB  have been determined and several polymor-
phisms have been identified among these genes [22,23].
As suggested by previous studies showing an association
between EDN1 polymorphism and asthma [24] or atopy
[25], we hypothesised that molecular variations in theses
genes could be a major determinant of the degree of bron-
chial obstruction in asthmatic patients. The purpose of
this study was therefore to investigate whether genetic
polymorphisms of preproET-1, EDNRA and EDNRB genes
were associated with the degree of airway obstruction
assessed by the forced expiratory volume in one second
(FEV1). We chose to concentrate our project on polymor-
phisms for which heterozygotes are frequent : 1/the G to
T substitution located in exon 5 at position 595 of the pre-
proET-1 gene (preproET-1-595G>T)(rs5370) [22], 2/the
C to T substitution located in exon 8 at position 1363 of
the EDNRA gene (EDNRA-1363C>T)(rs5333) [23] and 3/
the G to A substitution located in exon 4 at position 30 of
the EDNRB gene (EDNRB-30G>A)(rs5351) [23]. We first
genotyped a population of 162 adult asthmatic patients
recruited from our outpatient clinic and found a strong
association between the polymorphism of EDNRB and
FEV1. No association was found with the EDNRA or the
preproET-1 genes. To test the reproducibility of this associ-
ation observed between EDNRB and FEV1, we performed
a similar analysis, focusing on the EDNRB polymorphism,
on a larger group of adult subjects recruited from the gen-
eral population as part of the European Community Res-
piratory Health Survey (ECRHS II).
Methods
1. Hospital-based population of asthmatic patients
We studied 162 consecutive adult patients with asthma,
evaluated in the outpatient clinic of Bichat University
Hospital. Asthma was diagnosed on clinical grounds
according to the American Thoracic Society official state-
ment [26]. All patients were Caucasians, born in France,
and gave informed consent to participate in the study.
This study was approved by the ethical committee of
Bichat-Paris Nord.
A flow-volume curve was performed in all patients in a
stable condition at least one month after an acute exacer-
bation of asthma. The flow-volume curve was performed
according to the European Respiratory Society guidelines
[27]. The patients did not receive any bronchodilators
within 12 hours before the procedure. We analysed the
pre-bronchodilator FEV1 and the FEV1/FVC ratio.
2. Population-based sample of subjects recruited as part of 
the ECRHS
The European Community Respiratory Health Survey
(ECRHS) II is a multi-centre, international study in which
representative community based samples of young adults
have their lung function assessed on two occasions about
9 years apart. The methods for ECRHS I and ECRHS II
have been published in more detail elsewhere [28,29] and
further information is available from the study website
[30]. In ECRHS II, blood samples were taken in order to
extract DNA.
All subjects recruited in the centres of Grenoble, Montpel-
lier and Paris (France), born in France, for whom spirom-BMC Pulmonary Medicine 2007, 7:5 http://www.biomedcentral.com/1471-2466/7/5
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etry data for both ECRHS I and ECRHS II and blood
samples were available, were eligible for this study. The
sex-ratio did not differ between the 653 eligible and 732
ineligible subjects (including 493 subjects lost to follow-
up, 220 without blood sample and 19 with blood sample
but unsatisfactory spirometry). Eligible subjects were
slightly older and more likely to be non-smokers than
ineligible subjects (data not shown). For the analyses, we
included the eligible subjects who were genotyped for the
EDNRB  polymorphism (n = 632) : 21 subjects were
excluded as the genotype was not available; they did not
differ from the other eligible subjects in terms of age, sex-
ratio, smoking status, and FEV1. Subjects who answered
positively to the question "Have you ever had asthma ?"
were considered as asthmatics.
Written informed consent was obtained from each subject
before inclusion and the protocol was approved by the
French Ethics Committee for Human Research and by the
National Committee for Data Processing and Freedom.
3. Determination of preproET-1, EDNRA and EDNRB 
genotypes
Each genetic polymorphism was studied from genomic
DNA that was obtained from blood leukocytes, using
standard phenol extraction as previously described [31].
Genotyping of these polymorphisms was conducted using
an adapted method of DNA amplification by polymerase
chain reaction (PCR) procedure, with specific primers.
PCR products were digested by specific restriction
enzymes and separated by appropriate agarose gel electro-
phoresis.
• PreproET-1 gene polymorphism
The preproET-1 gene is located on chromosome 6p23-24.
The G to T transition at nucleotide 595 in exon 5 abolishes
one Ban II restriction site. Amplification of a 320-bp frag-
ment was performed using specific primers (5'-ATGATC-
CCAAGCTGAAAGGCG-3' and 5'
GCTGAGAGGTCCATTGTCATCC-3'). After initial dena-
turation at 94°C for 5 min., amplification was performed
in a DNA thermocycler (Gene Amp PCR System, Perkin
Elmer ; denaturation : 40 s at 94°C, annealing: 30s at
55°C, extension : 40 s at 72°C, 35 cycles). The genotypic
polymorphism was defined as GG (wild homozygote), GT
(heterozygote) and TT (mutated homozygote).
• EDNRA gene polymorphism
The EDNRA gene located in the short arm of the chromo-
some 4 presents a C to T substitution located in exon 8 at
1363 position. Amplification of a 297-bp fragment using
specific mutagenic primers (5'-GAAGTCTAAAACACAC-
CTAAGA-3' and 5'-TAGGTTCATACTGAAAACCCTAA-3'
underlined nucleotide represents the mutated nucle-
otide), introduces a DdeI restriction site on the normal C
allele which is lost on the mutated T allele. After initial
denaturation at 94°C for 5 min, amplification was per-
formed (denaturation : 40 s at 94°C, annealing: 30s at
50°C, extension: 40 s at 72°C, 35 cycles). The genotypic
polymorphism was defined as CC (wild homozygote), CT
(heterozygote) and TT (mutated homozygote).
• EDNRB gene polymorphism
The EDNRB gene is located on the chromosome 13q22
and presents a G to A substitution located in exon 4 at
position 30. Amplification of a 147-bp fragment using
specific mutagenic primers (5'-GACAGCAAAAGATTGGT-
GGAT-3' and 5'-CTTACCTGCTTTAGGTATC-3'), intro-
duces a Fok I restriction site on the normal G allele which
is abolished on the A allele. After initial denaturation at
94°C for 5 min, amplification was performed (denatura-
tion : 30 s at 94°C, annealing: 40s at 46°C, extension: 40
s at 72°C, 35 cycles). The genotypic polymorphism was
defined as GG (wild homozygote), GA (heterozygote) and
AA (mutated homozygote).
The results of genotyping of 200 patients were consistent
with the nucleotide sequence of exons 1–7 previously
determined on an automated sequencer.
4. Relative quantification of mRNA transcribed from each 
allele of the ETB receptor gene
In order to test the hypothesis that the EDNRB-30G>A
polymorphism could alter EDNRB mRNA level, we quan-
tified the mRNAs transcribed from each allele of the gene.
For that purpose, we analysed lung cDNA from 12 heter-
ozygote patients for the ETB/G30A polymorphism. Lung
samples were obtained at the time of surgery for lung can-
cer, in a macroscopically normal area.
Total mRNA of heterozygote patients was extracted from
homogenized lung tissues using TRIZOL reagent (Life
Technologies, France). For cDNA synthesis, reverse tran-
scription was performed by use of random hexamer (50
ng/μl) (Pharmacia, Guyancourt, France) and 10 U/μl
Superscript II (Gibco France) in presence of 1 μg of RNA,
0.5 mM dNTPs (Pharmacia, Guyancourt, France), 10 mM
dithiothreitol, 0.1 μg/μl BSA and 1U/μl of Rnasine
(Promega, Charbonnières, France). The mixture was incu-
bated at 42°C for 60 minutes. Polymerase chain reaction
was used to amplify cDNAs with specific primers : E3S : 5'-
TTG CTT CAT CCC GTT CAG A-3' and E4AS 5' biotin-CAC
CTT TTC TTT CTC AAC AT-3'. The extension assay was per-
formed by the dideoxy chain termination method with a
fluorescent primer (5'fluorescein-AAG ACA GCA AAA
GAT TGG TGG-3') finishing at two bases from the G30A
polymorphism according to a previously described proce-
dure [31,32]. The substitution of dATP by ddATP in the
termination mixture resulted in the synthesis of allele-spe-
cific extension products of 24 bases and 28 bases for A andBMC Pulmonary Medicine 2007, 7:5 http://www.biomedcentral.com/1471-2466/7/5
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G alleles respectively. After migration on an automated
sequencer (ABI PRISM 310, Applied Biosystem, France),
both products were detected as fluorescent peaks. The
ratio of area under the curve of both detected peaks from
each sample of heterozygote patient was determined with
the Genescan analysis software (Applied Biosystem,
France). The ratio of area under the curve for the two
peaks was close to 1 when genomic DNAs from heterozy-
gote patients was used.
5. Sequence analysis of ETB cDNA from lung tissues
In order to test for a possible existence of other mutations
of the EDNRB gene in linkage disequilibrium with the
EDNRB-30G>A polymorphism, the nucleotide sequence
of exons 1–7 of lung cDNA obtained from 10 heterozy-
gote patients was determined on an automated sequencer.
The entire coding region was obtained in two overlapping
amplification products on cDNA with the following prim-
ers: ETB 1 bis 5'-ACC GGA CGC CTT CTG GAG CA-3' and
ETB 3AS 5'-ACA ATT TCT ACT GCT CAT-3', ETB 2S 5'-GAG
CTG TTG CTT CTT GGA GTA-3' and ETB 7AS 5'-AAT GAC
TTC GGT CCA ATA TAA-3'.
6. Statistical analysis
• Asthmatic population
Allele frequencies and genotypes repartition were
counted. Functional respiratory parameters (FEV1 as % of
predicted value and FEV1/FVC ratio) are expressed as
mean value ± SD. Differences between the studied groups
defined according to the genotypes were evaluated by 2-
way analysis of variance (ANOVA); the significance level
was fixed at 5% (p values less than 0.05).
• ECRHS II population
For the EDNRB, we either analysed the 3 genotypes sepa-
rately or pooled genotypes AA and AG compared to geno-
type GG. FEV1 as %predicted and FEV1/FVC ratio were
considered as continuous variables, and analysed using
ANOVA. Subjects with FEV1 %predicted lower or equal to
80% were considered to have airway obstruction. Statisti-
cal differences in the frequency of airway obstruction were
tested using Chi-square tests, or Fisher Exact test when the
numbers were too low. This outcome was adjusted for
confounders in binary logistic regressions. Confounding
factors included sex, centre and smoking status (coded in
4 classes: never-smokers, ex-smokers (>1 year), moderate
and heavy smokers (smokers and ex smokers < 1 yr, with
< 20 cig/day and ≥ 20 cig/day, respectively). To make sure
of the lack of stratification in the underlying population
for the polymorphism, Hardy-Weinberg structure was
tested. All statistics were computed with SAS software
package (SAS Institute, Cary NC, USA).
• Lung mRNA transcription
The ratio of area under the curves of both detected peaks
obtained from cDNA was compared to the ratio obtained
from genomic DNA of heterozygote patients. Data were
expressed as mean + standard deviation and analyzed
using t test for paired data. Significance for all statistics
was accepted at P < 0.05.
Results
1. Lung function and genotype in asthmatic patients
• Pulmonary function tests and frequencies of genotypes in asthmatic 
patients
Patients were 86 women and 76 men, with a mean age of
46.3 (± 16 years). All were never smokers; 30.8% had total
serum IgE levels higher than 100 UI/ml. In the whole pop-
ulation, mean FEV1 amounted to 73.7 ± 21.20 % of pre-
dicted values and mean FEV1/FVC ratio was 65.5 ± 15.5
%. The distribution of genotypes for each polymorphism
is presented in table 1 and was similar to previoulsy
reported data in the general population (21, 22). EDNRB
polymorphism displayed a Hardy-Weinberg structure.
• Relationship between genotypes, FEV1 and FEV1/FVC in asthmatic 
patients
The preproET-1 gene and the EDNRA gene polymorphisms
did not correlate with any of the pulmonary functional
parameters studied (data not shown). By contrast, the
EDNRB gene polymorphism was significantly related to
the FEV1 value (p = 0.0039). Indeed, mean FEV1 was lower
in the homozygotes GG (68.7 ± 19.2%) than in patients
with one or more allele A (76.9 ± 21.9%, p = 0.016) (table
2). FEV1 tended to be lower in heterozygotes GA than in
mutated homozygotes AA, without reaching statistical sig-
nificance. The FEV1/FVC ratio was similar in the different
groups. However, FEV1/FVC ratio tended to be lower (p =
0.086) and the percentage of patients with airway obstruc-
tion tended to be higher (p = 0.09) in homozygotes GG
than in AA+AG patients (table 2).
Although uneven distribution of the sex ratio in the differ-
ent genotypes could participate in the higher FEV1 meas-
ured in mutated homozygotes (27), this variable was not
different according to the EDNRB  genotype (AA :10
women, 13 men, GA : 44 women, 31 men and GG : 32
women, 32 men, p = 0.36). Moreover, the mean age of the
patients did not differ in relation to the EDNRB genotype
(AA: 42 ± 15 years, GA : 50 ± 17 years and GG: 48 ± 15
years, p = 0.2).
2. Results from ECRHS
In ECRHS II, the subjects were aged 44.3 ± 7.2 yr and
approximately half of the subjects were men. Forty-three
percent were never-smokers, 29.7% were ex-smokers,
18.7% were moderate smokers (< 20 cig/day) and 8.6%
were heavy smokers (≥ 20 cig/day). As expected in thisBMC Pulmonary Medicine 2007, 7:5 http://www.biomedcentral.com/1471-2466/7/5
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young adult population, subjects showed normal FEV1
values (105.7 ± 14.3 %predicted). Among the 632 French
subjects included, only 4.3% (n = 27) had airway obstruc-
tion as defined by a FEV1 = 80%predicted. Genotypic dis-
tribution in the 3 centres is shown in Table 3. Overall,
genotypes AA, AG and GG accounted for 17.3%, 48.1%
and 34.7%, respectively. EDNRB  polymorphism dis-
played a Hardy-Weinberg structure in all centres, as well
as following pooling of all centres.
The prevalence of airway obstruction (FEV1 = 80%pre-
dicted) was higher among subjects genotyped GG than in
those genotyped AA or AG. In multivariate logistic regres-
sion, the risk of airway obstruction was not different
between centres or between men and women. Heavy
smokers had a four-fold increased risk compared to non-
smokers (adjusted Odds-Ratio (OR) = 4.04 (95% Confi-
dence Interval (CI) 1.22–13.43). When pooling together
subjects with AA and AG genotypes, and after adjustment
for centre and smoking, the risk of airway obstruction was
higher in the subjects carrying the GG genotype, as com-
pared to other subjects (OR = 3.19 (95%CI 1.43 – 7.15)).
When the analysis was run separately in never smokers to
discard any possible residual confounding by tobacco,
there was a tendency for a higher frequency of airway
obstruction in GG subjects as compared to AA+GA (7.1%
vs. 0.6%, respectively, p = 0.004 using Fisher's exact test).
However the prevalence of airway obstruction was very
low in this group of subjects (2.97%, overall), and no
association was observed for FEV1 %predicted or FEV1/
CVF ratio. Only 54 subjects were considered as heavy
smokers at the time of the survey. In order to assess the
association in subjects at risk of airway obstruction
because of tobacco smoking, we analysed separately the
201 subjects who reported a cumulative history of smok-
ing of more than 12 pack years. When smokers who
cumulated more than 12 pack-years were considered, the
prevalence of airway obstruction reached 4.97%. In this
group, airway obstruction was significantly more frequent
in GG subjects (adjusted OR = 7.42 (95%CI 1.69 – 32.6))
and the FEV1 %predicted was lower in carriers of the GG
genotype as compared to AA+AG (table 4). Similar results
were obtained when the analysis was further restricted to
the 118 subjects with a cumulated history of smoking of
more than 20 pack years (results not shown).
Finally, the analysis was conducted in subjects who
reported to have ever had asthma. Similarly to what was
observed in the sample of asthmatic patients recruited at
the University clinic, there was a tendency for both




n (%) n (%) n (%)
GG 101 (62.3%) CC 80 (49.4%) GG 64 (39.5%)
GT 55 (34%) CT 67 (41.3%) GA 75 (46.3%)
TT 6 (3.3%) TT 15 (9.3%) AA 23 (14.2%)
Allele 
frequencies
G 0.79 C 0.70 G 0.63
T 0.21 T 0.30 A 0.37
Table 2: Differences in lung function measurements and prevalence of airway obstruction according to the EDNRB genotype in the 
hospital-based population of asthmatic patients.
FEV1 (%predicted) FEV1/FVC FEV1= 80%pred
mean (SD) mean (SD) % (n)
AA (n = 23) 85.65 (22.6) 67.65 (14.7) 43.5 (10)
AG (n = 75) 74.2 (21.2) 67 (15.7) 61.3 (46)
GG (n = 64) 68.75 (19.2) 62.82 (15.8) 78.1 (45)
p 0.0039 0.22 0.072
AG+AA (n = 98) 76.9 (21.9) 67.15 (15.4) 57.42(56)
GG (n = 64) 68.7 (19.2) 62.8 (15.8) 70.3 (45)
p 0.016 0.086 0.09BMC Pulmonary Medicine 2007, 7:5 http://www.biomedcentral.com/1471-2466/7/5
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FEV1%predicted and FEV/FVC ratio to be lower in GG
subjects compared to AA+AG subjects (table 4). In sub-
jects with asthma recruited in ECRHS, the prevalence of
airway obstruction was 12.6%, and it was more frequent
in GG subjects compared to AA+AG (adjusted OR = 4.31
(95%CI 1.03 – 18.04)).
3. Relative quantification of ETB mRNA transcribed from 
each allele of the gene
In order to determine whether the EDNRB-30G>A poly-
morphism modified the expression of the EDNRB gene,
we quantified the relative level of EDNRB mRNA for each
allele (wild and mutated) in 12 heterozygote patients. For
each patient, the ratio of area under the curve of the fluo-
rescent peaks specific for each allele was similar in cDNA
and genomic DNA (mean values : 0.98 ± 0.079 and 1.01
± 0.082, p = 0.8). This indicated that the steady state
mRNA level for the mutated allele (A) and the wild allele
(G) was not altered.
4. Sequence analysis of EDNRB cDNA
The sequence analysis of the EDNRB cDNA was per-
formed in10 patients, heterozygotes for the EDNRB-
30G>A polymorphism. No further mutation was detected
on the entire coding sequence of the ETB receptor gene,
ruling out other mutations of the EDNRB gene in linkage
disequilibrium with the EDNRB-30G>A polymorphism.
Discussion
The main results of this study are : 1) the 30G>A SNP in
EDNRB is strongly associated with a low FEV1 in a popu-
lation of adult asthmatic patients; 2) no relationship was
found between pulmonary function and EDNRA or pre-
proET-1 polymorphism; 3) in a large population of adults
from the general population, a similar association
between low FEV1 and GG genotype was found, with sim-
ilar results observed in the subgroups of asthmatic and
heavy smokers. Altogether, these data emphasize that
EDNRB polymorphism could be a determinant of airway
obstruction in patients with predisposing factors.
As EDN1 displays physiological effects in the airways, the
initial purpose of this study was to look for a possible
association between FEV1 in asthma and the genetic differ-
ences in the endothelin system in asthmatic patients. We
investigated genetic polymorphisms with high mutated
allelic frequency in the general population : the 595G>T
polymorphism of the gene coding for the preproET-1 (21),
the 1363C>T polymorphism of the EDNRA gene (22) and
the 30G>A polymorphism of the EDNRB gene (22). In
our asthmatic population, for each polymorphism, the
observed genotypes repartition and allelic frequencies
were similar to previously reported data obtained in cau-
casian populations (21,22). These repartitions do not sup-
port an association between these polymorphisms and
asthma. In a Czech population, no association between
polymorphism for the intron 4 (position 8000) in the
EDN1 gene and asthma or atopy was observed [33]. In a
British and a Japanese population studying other genetic
variants of the preproET-1, EDNRA and EDNRB genes, no
association was observed with asthma (28). The variants
of the EDNRA gene showed a marginal association with
atopy in the British population but no association in the
Japanese population of asthmatics. We cannot compare
our results with the latter study since they did not measure
pulmonary function (28).
Our asthmatic patients were exclusively recruited from
our university hospital, leading probably to a selection
bias of more severe patients. However, we have no argu-
ment to support that this could influence the relationship
between the EDNRB gene polymorphism and the degree
of airway obstruction assessed by FEV1. To finish with,
since we did not genotype any random markers, we can-
not completely rule out population stratification as an
explanation for our results.
In the hospital-based asthmatic population, we found a
strong association between the EDNRB-30G>A SNP and
the degree of airway obstruction. Indeed, FEV1 values were
lower in GG patients than in AA+AG patients, and tended
Table 3: Frequencies of genotypes and alleles for EDNRB-30G>A among the ECRHS population
Grenoble (n = 232) Montpellier (n = 128) Paris (n = 272) Total (n = 632)
Genotype, %
AA 16.8 21.9 15.4 17.3
AG 47.0 46.9 49.6 48.1
GG 36.2 31.3 34.9 34.7
Allele, %
A 40.3 45.3 40.3 41.3
G 59.7 54.7 59.7 58.7BMC Pulmonary Medicine 2007, 7:5 http://www.biomedcentral.com/1471-2466/7/5
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to be lower in AG patients than in AA patients. Most
importantly, in a population-based sample of subjects
recruited as part of the ECRHS, we observed that the per-
centage of subjects with FEV1 % predicted below 80% was
higher in GG subjects than in AG+AA subjects. As we ana-
lysed the subgroup of asthmatic subjects in this popula-
tion, we again found a strong association between the
EDNRB-30G>A SNP and the degree of airway obstruction.
Interestingly, a similar correlation was observed in the
subgroup of smokers, whereas when focusing on never
smokers, such a correlation was not observed. Our results
suggest that the GG genotype may contribute to the devel-
opment of airway obstruction in subjects with predispos-
ing conditions, such as asthmatic inflammation or
tobacco exposure. Bronchial hyperresponsiveness has
been associated with the long term development of airway
obstruction in asthma and in smokers [34]. However, in
the present study, the EDNRB  polymorphism did not
influence the prevalence of bronchial hyperresponsive-
ness in the ECRHS group (data not shown).
To date, the mechanism of the association between
EDNRB genotype and FEV1 is unknown. Numerous stud-
ies have demonstrated the role of EDNR1 on bronchial
smooth muscle contraction (via  intracellular calcium
input and modulation of acetylcholine or relaxant sub-
stances such as prostanoids or nitric oxide secretion), but
also on mucus secretion, airway remodelling and inflam-
mation, all features contributing to airway obstruction in
asthmatics and smokers [35]. Since the EDNRB 30G>A
polymorphism is a silent mutation (22) that does not
modify the amino acid sequence of the protein, we imag-
ined that this mutation could modify the transcription of
the gene and/or the stability of the mRNA either directly
or by a linkage disequilibrium with a mutation located in
the regulating region of the gene. To investigate this point,
we performed a relative quantification of mRNAs tran-
scribed from each allele. We found no allelic difference in
the mRNA level in heterozygote patients for the EDNRB-
30G>A polymorphism. Thus, we can suggest that this pol-
ymorphism is unlikely to modify the expression of the
EDNRB mRNA. We could then hypothetise that the
EDNRB-30G>A polymorphism is in linkage disequilib-
rium with a non silent mutation located in the coding
region of the gene. However, we found no difference in
the nucleotide sequence from G and A alleles of the
EDNRB cDNA from 10 heterozygote patients, making
unlikely this possibility. However, we cannot rule out that
the EDNRB-30G>A polymorphism may be in linkage dis-
equilibrium with a mutation located in another gene near
Table 4: Differences in lung function measurements and prevalence of airway obstruction according to the ETB genotype in the 
ECRHS population
FEV1 (%predicted)* FEV1/FVC* FEV1 ≤ 80%pred
mean (SE) mean (SE) % (n)
All patients (n = 632)
AA (n = 109) 104.8 (1.36) 84.2 (0.7) 4.6 (5)
AG (n = 304) 107.0 (0.81) 83.4 (0.4) 2.0 (6)
GG (n = 219) 104.4 (0.95) 83.2 (0.5) 7.3 (16)
p 0.09 0.47 0.012
AG+AA (n = 413) 106.4 (0.70) 83.6 (0.3) 2.7 (11)
GG (n = 219) 104.4 (0.96) 83.2 (0.5) 7.3 (16)
p 0.09 0.55 0.005
Never smokers (n = 269)
AG+AA (n = 170) 107.4. (1.1) 84.3 (0.5) 0.6 (1)
GG (n = 99) 105.9 (1.4) 83.6 (0.7) 7.1 (7)
p 0.39 0.40 -†
Smokers ≥ 12 pack-Years (n = 201)
AG+AA (n = 138) 105.7 (1.2) 81.9 (0.6) 2.2 (3)
GG (n = 63) 99.6 (1.8) 82.4 (0.9) 11.1 (7)
p 0.007 0.6 0.007
Asthmatics (n = 87)
AG+AA (n = 52) 102.8 (2.4) 81.2 (1.1) 5.8 (3)
GG (n = 35) 93.1 (2.9) 77.9 (1.4) 22.9 (8)
p 0.012 0.07 0.02
* adjusted for centre and smoking habits for FEV1%predicted, adjusted for centre, sex and smoking habits for FEV1%CVF.
† Chi-square statistic not valid.BMC Pulmonary Medicine 2007, 7:5 http://www.biomedcentral.com/1471-2466/7/5
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to the EDNRB locus in 13q22, a previously described
region as an asthma susceptibility locus (29). Further
studies are under way to explore this hypothesis.
Conclusion
In summary, the present study is the first report for a
strong association between the EDNRB-30G>A polymor-
phism and the degree of airway obstruction, especially in
patients with factors predisposing to airway remodelling
such as asthma or smoking. Further studies, including
complete sequencing of the EDNRB gene and comprehen-
sive assessment of it in other populations, are clearly
needed, to confirm this association in asthmatic patients,
to determine whether this association exists in other air-
way obstructive disease such as COPD and to understand
its biological pathways.
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